Independence Blue Cross began limiting coverage of GLP-1 drugs on Jan. 1 to some medical conditions, but not obesity or weight loss.

Telehealth stock Hims & Hers ( HIMS) spiked more than 24% in trading Thursday, days after its Super Bowl ad promoting cheaper GLP-1 weight-loss drugs sparked controversy.

Food and drug companies have expressed optimism, but the new health secretary and his MAHA movement will likely make waves.

It’s possible that GLP-1s may be useful for a range of substance use disorders, including opioid use disorder and nicotine ...

Over $600 billion in European goods were imported by the U.S. last year. New tariffs from President Trump will likely hit ...

As demand remains high for GLP-1 drugs, primary care physicians are concerned about the risks of patients using third-party ...

The GLP-1 liraglutide showed potential benefit in reducing stroke recurrence and improving functional outcomes after minor ...

Dr Pandey shares key insights on dosing, monitoring, and patient education to sustain therapy and improve outcomes. Essential for cardiologists and PCPs!

Antibody-drug conjugates have emerged as ... Even more recently, AbbVie has joined the list of big pharma admirers of ADCs to launch a $10.1 billion deal to acquire ImmunoGen.